secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-05-13T10:57:15+00:00
Accession:  0001104659-26-059749
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance
--------------------------------------------------------------------------------

- Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.
- PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.
- Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.
- Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/0001104659-26-059749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer